Bolt Biotherapeutics Inc
BOLT
Market Cap$13.55M
Close$
Share Statistics
| Market cap | $13.55 Million |
|---|---|
| Enterprise Value | $34.57 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.65 |
| Beta | 0.96 |
| Outstanding Shares | 38,285,490 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.21 |
|---|---|
| PEG | 3.22 |
| Price to Sales | - |
| Price to Book Ratio | 0.37 |
| Enterprise Value to Revenue | 3.54 |
| Enterprise Value to EBIT | -0.48 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.82 |
| Debt to Equity | 0.49 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Bolt Biotherapeutics Inc
65 employeesBolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjug...